Mercer Global Advisors Inc. ADV Sells 9,459 Shares of Boston Scientific Co. (NYSE:BSX)

Mercer Global Advisors Inc. ADV trimmed its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 73,875 shares of the medical equipment provider's stock after selling 9,459 shares during the period. Mercer Global Advisors Inc. ADV's holdings in Boston Scientific were worth $6,599,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. TFC Financial Management Inc. lifted its stake in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. Valley National Advisers Inc. lifted its stake in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares in the last quarter. Fairway Wealth LLC purchased a new position in Boston Scientific in the 4th quarter valued at approximately $36,000. Finally, Global Trust Asset Management LLC lifted its position in shares of Boston Scientific by 64.5% during the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 171 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. This trade represents a 11.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president now owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 300,497 shares of company stock valued at $31,056,815 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on BSX shares. Truist Financial raised their target price on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. BTIG Research reiterated a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. UBS Group upped their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Needham & Company LLC lifted their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Finally, Wells Fargo & Company increased their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $114.52.

Boston Scientific Stock Down 0.4 %

Shares of BSX traded down $0.42 on Friday, hitting $102.87. 3,604,604 shares of the stock traded hands, compared to its average volume of 6,332,074. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a market capitalization of $152.19 billion, a PE ratio of 82.30, a P/E/G ratio of 2.79 and a beta of 0.68. The business has a 50 day simple moving average of $98.70 and a 200 day simple moving average of $95.83. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.56 EPS. As a group, equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.